nafamostat has been researched along with Disease Models, Animal in 33 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to evaluate the effects of nafamostat, a serin protease inhibitor, in the management of subarachnoid hemorrhage (SAH)." | 8.12 | Nafamostat protects against early brain injury after subarachnoid hemorrhage in mice. ( Egashira, Y; Enomoto, Y; Hara, H; Imai, T; Iwama, T; Matsubara, H; Nakamura, S; Nakayama, N; Oka, N; Shimazawa, M; Tsuji, S, 2022) |
| "To clarify the involvement of serine proteases in the development of allergic airway inflammation, we investigated the effect of nafamostat mesilate, a serine protease inhibitor, in a murine model of allergic asthma." | 7.74 | Nafamostat mesilate, a potent serine protease inhibitor, inhibits airway eosinophilic inflammation and airway epithelial remodeling in a murine model of allergic asthma. ( Inagaki, N; Ishizaki, M; Kajiwara, D; Nagai, H; Tanaka, H; Toyohara, T; Wakahara, K, 2008) |
| "Effects of dermatan sulfate (DS) on the endotoxin-induced disseminated intravascular coagulation (DIC) rat model were compared with those of low-molecular weight heparin (LMWH), nafamostat mesilate (NM) and argathroban (AR)." | 7.70 | Effects of dermatan sulfate, a heparin cofactor II mediated thrombin inhibitor, on the endotoxin-induced disseminated intravascular coagulation model in the rat: comparison with low-molecular weight heparin, nafamostat mesilate and argathroban. ( Horie, K; Kyogashima, M; Miyauchi, S; Mizuno, S; Onaya, J; Sunose, A, 1998) |
| "Trypsinogen activation peptide (TAP) concentration and alpha 2-macroglobulin-trypsin complex (alpha 2M-T) activity were measured in two experimental models of acute pancreatitis in rats to evaluate the significance of activation of trypsinogen in acute pancreatitis." | 7.69 | Activation of trypsinogen in experimental models of acute pancreatitis in rats. ( Hayakawa, T; Hirao, S; Kitagawa, M; Nakae, Y; Naruse, S; Yamamoto, R, 1995) |
| "Nafamostat mesilate treatment significantly improved locomotion recovery as assessed by hindlimb BBB scores and the inclined plane test." | 5.48 | Nafamostat mesilate attenuates inflammation and apoptosis and promotes locomotor recovery after spinal cord injury. ( Duan, HQ; Fan, BY; Feng, SQ; Kong, XH; Li, B; Shi, HY; Sun, C; Wu, QL; Yao, X; Zhang, Y; Zhao, CX; Zhou, XF, 2018) |
| "After transient middle cerebral artery occlusion (tMCAO) in rats, NM reduced the infarct size, improved behavioral functions, decreased the expression of proinflammatory mediators (TNF-α, IL-1β, iNOS and COX-2) in a time-dependent manner and promoted the expression of different anti-inflammatory factors (CD206, TGF-β, IL-10 and IL-4) at different time points." | 5.43 | Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats. ( Chen, T; Fang, Y; Li, C; Liao, H; Liu, Y; Sun, H; Wang, J; Zhou, XF, 2016) |
| "Colitis was induced in female BALB/c mice by 5% dextran sulfate sodium (DSS) for 6 days." | 5.37 | Nafamostat mesilate attenuates colonic inflammation and mast cell infiltration in the experimental colitis. ( Ahn, JY; Cho, EY; Choi, SC; Im, LR; Kim, DK; Kim, JH; Kwon, SU; Lee, SH; Lee, YM; Xin, M, 2011) |
| "This study aimed to evaluate the effects of nafamostat, a serin protease inhibitor, in the management of subarachnoid hemorrhage (SAH)." | 4.12 | Nafamostat protects against early brain injury after subarachnoid hemorrhage in mice. ( Egashira, Y; Enomoto, Y; Hara, H; Imai, T; Iwama, T; Matsubara, H; Nakamura, S; Nakayama, N; Oka, N; Shimazawa, M; Tsuji, S, 2022) |
| " However, the effects of the serine protease inhibitors nafamostat mesilate (FUT), gabexate mesilate (FOY), and ulinastatin (UTI) on a long-term challenged mouse model of chronic asthma are unclear." | 3.80 | The effect of serine protease inhibitors on airway inflammation in a chronic allergen-induced asthma mouse model. ( Chao, YP; Chiang, CJ; Kao, ST; Lin, CC; Lin, J; Lin, LJ; Wang, SD, 2014) |
| "The established referred allodynia/hyperalgesia following cerulein treatment was abolished by post-treatment with nafamostat mesilate, a proteinase inhibitor, and with capsazepine, a TRPV1 antagonist, in mice." | 3.76 | The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice. ( Akashi, R; Ishikura, H; Kawabata, A; Kitamura, T; Matsumura, K; Matsunami, M; Naruse, M; Nishimura, S; Sekiguchi, F; Shinozaki, Y, 2010) |
| "To clarify the involvement of serine proteases in the development of allergic airway inflammation, we investigated the effect of nafamostat mesilate, a serine protease inhibitor, in a murine model of allergic asthma." | 3.74 | Nafamostat mesilate, a potent serine protease inhibitor, inhibits airway eosinophilic inflammation and airway epithelial remodeling in a murine model of allergic asthma. ( Inagaki, N; Ishizaki, M; Kajiwara, D; Nagai, H; Tanaka, H; Toyohara, T; Wakahara, K, 2008) |
| "Effects of dermatan sulfate (DS) on the endotoxin-induced disseminated intravascular coagulation (DIC) rat model were compared with those of low-molecular weight heparin (LMWH), nafamostat mesilate (NM) and argathroban (AR)." | 3.70 | Effects of dermatan sulfate, a heparin cofactor II mediated thrombin inhibitor, on the endotoxin-induced disseminated intravascular coagulation model in the rat: comparison with low-molecular weight heparin, nafamostat mesilate and argathroban. ( Horie, K; Kyogashima, M; Miyauchi, S; Mizuno, S; Onaya, J; Sunose, A, 1998) |
| "Trypsinogen activation peptide (TAP) concentration and alpha 2-macroglobulin-trypsin complex (alpha 2M-T) activity were measured in two experimental models of acute pancreatitis in rats to evaluate the significance of activation of trypsinogen in acute pancreatitis." | 3.69 | Activation of trypsinogen in experimental models of acute pancreatitis in rats. ( Hayakawa, T; Hirao, S; Kitagawa, M; Nakae, Y; Naruse, S; Yamamoto, R, 1995) |
| "Nafamostat mesilate treatment significantly improved locomotion recovery as assessed by hindlimb BBB scores and the inclined plane test." | 1.48 | Nafamostat mesilate attenuates inflammation and apoptosis and promotes locomotor recovery after spinal cord injury. ( Duan, HQ; Fan, BY; Feng, SQ; Kong, XH; Li, B; Shi, HY; Sun, C; Wu, QL; Yao, X; Zhang, Y; Zhao, CX; Zhou, XF, 2018) |
| "After transient middle cerebral artery occlusion (tMCAO) in rats, NM reduced the infarct size, improved behavioral functions, decreased the expression of proinflammatory mediators (TNF-α, IL-1β, iNOS and COX-2) in a time-dependent manner and promoted the expression of different anti-inflammatory factors (CD206, TGF-β, IL-10 and IL-4) at different time points." | 1.43 | Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats. ( Chen, T; Fang, Y; Li, C; Liao, H; Liu, Y; Sun, H; Wang, J; Zhou, XF, 2016) |
| "In infants with biliary atresia, hepatic Granzymes A and B mRNA, but not Perforin, increased at the time of portoenterostomy." | 1.40 | Perforin and granzymes work in synergy to mediate cholangiocyte injury in experimental biliary atresia. ( Bezerra, JA; Mourya, R; Shivakumar, P, 2014) |
| "Colitis was induced in female BALB/c mice by 5% dextran sulfate sodium (DSS) for 6 days." | 1.37 | Nafamostat mesilate attenuates colonic inflammation and mast cell infiltration in the experimental colitis. ( Ahn, JY; Cho, EY; Choi, SC; Im, LR; Kim, DK; Kim, JH; Kwon, SU; Lee, SH; Lee, YM; Xin, M, 2011) |
| "Nafamostat mesilate (NM) is a broad-range synthetic protease inhibitor with some anti-inflammatory action." | 1.34 | Nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury. ( Hagiwara, S; Iwasaka, H; Noguchi, T, 2007) |
| "After the induction of severe acute pancreatitis, rats received intravenous or regional intraarterial infusion of nafamostat and then concentrations of trypsinogen activated peptide (TAP) and serum interleukin (IL-6), and histologic sections of the pancreas were examined and the 96-hour survival rate was evaluated." | 1.33 | Rat experimental model of continuous regional arterial infusion of protease inhibitor and its effects on severe acute pancreatitis. ( Egawa, S; Fukuyama, S; Matsuda, K; Matsuno, S; Mikami, Y; Qiu-Feng, H; Sunamura, M; Takeda, K, 2005) |
| "Intestinal and lung injury was assessed at 3 h after resuscitation with Ringer's lactate solution." | 1.32 | Serine proteases are involved in the pathogenesis of trauma-hemorrhagic shock-induced gut and lung injury. ( Deitch, EA; Feketeova, E; Lu, Q; Shi, HP; Xu, DZ, 2003) |
| "30% at 24 hours), and bacterial infection of the peritoneal fluid, mesenteric lymph nodes, and pancreas was completely prevented in group III." | 1.31 | Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model. ( Isaji, S; Takagi, K, 2000) |
| " When a new synthetic antiprotease (nafamstat mesilate) in a dosage of 0." | 1.27 | Toxic products in hemorrhagic ascitic fluid generated during experimental acute hemorrhagic pancreatitis in dogs and a treatment which reduces their effect. ( Koh, I; Nishiwaki, H; Satake, K; Umeyama, K, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.06) | 18.7374 |
| 1990's | 3 (9.09) | 18.2507 |
| 2000's | 11 (33.33) | 29.6817 |
| 2010's | 10 (30.30) | 24.3611 |
| 2020's | 7 (21.21) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Ianevski, A | 1 |
| Yao, R | 1 |
| Lysvand, H | 1 |
| Grødeland, G | 1 |
| Legrand, N | 1 |
| Oksenych, V | 1 |
| Zusinaite, E | 1 |
| Tenson, T | 1 |
| Bjørås, M | 1 |
| Kainov, DE | 1 |
| Matsubara, H | 1 |
| Imai, T | 1 |
| Tsuji, S | 1 |
| Oka, N | 1 |
| Egashira, Y | 1 |
| Enomoto, Y | 1 |
| Nakayama, N | 1 |
| Nakamura, S | 1 |
| Shimazawa, M | 1 |
| Iwama, T | 1 |
| Hara, H | 1 |
| Jeong, JH | 1 |
| Lee, WH | 1 |
| Min, SC | 1 |
| Kim, BK | 1 |
| Park, OB | 1 |
| Chokkakula, S | 1 |
| Ahn, SJ | 1 |
| Oh, S | 1 |
| Park, JH | 1 |
| Jung, JW | 1 |
| Jung, JM | 1 |
| Kim, EG | 1 |
| Song, MS | 1 |
| Kikuchi, K | 1 |
| Hamaue, N | 1 |
| Machida, T | 1 |
| Iizuka, K | 1 |
| Minami, M | 1 |
| Hirafuji, M | 1 |
| Albulescu, LO | 1 |
| Xie, C | 1 |
| Ainsworth, S | 1 |
| Alsolaiss, J | 1 |
| Crittenden, E | 1 |
| Dawson, CA | 1 |
| Softley, R | 1 |
| Bartlett, KE | 1 |
| Harrison, RA | 1 |
| Kool, J | 1 |
| Casewell, NR | 1 |
| Li, K | 1 |
| Meyerholz, DK | 1 |
| Bartlett, JA | 1 |
| McCray, PB | 1 |
| Duan, HQ | 1 |
| Wu, QL | 1 |
| Yao, X | 1 |
| Fan, BY | 1 |
| Shi, HY | 1 |
| Zhao, CX | 1 |
| Zhang, Y | 1 |
| Li, B | 1 |
| Sun, C | 1 |
| Kong, XH | 1 |
| Zhou, XF | 2 |
| Feng, SQ | 1 |
| Saito, N | 1 |
| Uwagawa, T | 2 |
| Hamura, R | 1 |
| Takada, N | 1 |
| Sugano, H | 1 |
| Shirai, Y | 1 |
| Shiba, H | 2 |
| Ohashi, T | 2 |
| Yanaga, K | 2 |
| Shivakumar, P | 1 |
| Mourya, R | 1 |
| Bezerra, JA | 1 |
| Lin, CC | 1 |
| Lin, LJ | 1 |
| Wang, SD | 1 |
| Chiang, CJ | 1 |
| Chao, YP | 1 |
| Lin, J | 1 |
| Kao, ST | 1 |
| Kwon, SK | 1 |
| Ahn, M | 1 |
| Song, HJ | 1 |
| Kang, SK | 1 |
| Jung, SB | 1 |
| Harsha, N | 1 |
| Jee, S | 1 |
| Moon, JY | 1 |
| Suh, KS | 1 |
| Lee, SD | 1 |
| Jeon, BH | 1 |
| Kim, DW | 1 |
| Kim, CS | 1 |
| Li, C | 1 |
| Wang, J | 1 |
| Fang, Y | 1 |
| Liu, Y | 1 |
| Chen, T | 1 |
| Sun, H | 1 |
| Liao, H | 1 |
| Phongsisay, V | 1 |
| Susuki, K | 1 |
| Matsuno, K | 1 |
| Yamahashi, T | 1 |
| Okamoto, S | 1 |
| Funakoshi, K | 1 |
| Hirata, K | 1 |
| Shinoda, M | 1 |
| Yuki, N | 1 |
| Ishizaki, M | 1 |
| Tanaka, H | 1 |
| Kajiwara, D | 1 |
| Toyohara, T | 1 |
| Wakahara, K | 1 |
| Inagaki, N | 2 |
| Nagai, H | 2 |
| Tsujii, K | 1 |
| Andoh, T | 1 |
| Ui, H | 1 |
| Lee, JB | 1 |
| Kuraishi, Y | 1 |
| La Bonte, LR | 1 |
| Dokken, B | 1 |
| Davis-Gorman, G | 1 |
| Stahl, GL | 1 |
| McDonagh, PF | 1 |
| Kim, HD | 1 |
| Malinoski, DJ | 1 |
| Borazjani, B | 1 |
| Patel, MS | 1 |
| Chen, J | 1 |
| Slone, J | 1 |
| Nguyen, XM | 1 |
| Steward, E | 1 |
| Schmid-Schonbein, GW | 1 |
| Hoyt, DB | 1 |
| Furukawa, K | 1 |
| Iida, T | 1 |
| Fujiwara, Y | 1 |
| Shimada, Y | 1 |
| Misawa, T | 1 |
| Nishimura, S | 1 |
| Ishikura, H | 1 |
| Matsunami, M | 1 |
| Shinozaki, Y | 1 |
| Sekiguchi, F | 1 |
| Naruse, M | 1 |
| Kitamura, T | 1 |
| Akashi, R | 1 |
| Matsumura, K | 1 |
| Kawabata, A | 1 |
| Cho, EY | 1 |
| Choi, SC | 1 |
| Lee, SH | 1 |
| Ahn, JY | 1 |
| Im, LR | 1 |
| Kim, JH | 1 |
| Xin, M | 1 |
| Kwon, SU | 1 |
| Kim, DK | 1 |
| Lee, YM | 1 |
| Keck, T | 1 |
| Yamauchi, J | 1 |
| Takeda, K | 2 |
| Shibuya, K | 1 |
| Sunamura, M | 2 |
| Matsuno, S | 2 |
| Deitch, EA | 1 |
| Shi, HP | 1 |
| Lu, Q | 1 |
| Feketeova, E | 1 |
| Xu, DZ | 1 |
| Mikami, Y | 1 |
| Matsuda, K | 1 |
| Qiu-Feng, H | 1 |
| Fukuyama, S | 1 |
| Egawa, S | 1 |
| Hagiwara, S | 1 |
| Iwasaka, H | 1 |
| Noguchi, T | 1 |
| Nakanowatari, Y | 1 |
| Nemoto, K | 1 |
| Hara, S | 1 |
| Ninomiya, N | 1 |
| Yamamoto, Y | 1 |
| Yamada, H | 1 |
| Matsuura, N | 1 |
| Shimazawa, T | 1 |
| Koda, A | 1 |
| Nakae, Y | 1 |
| Naruse, S | 1 |
| Kitagawa, M | 1 |
| Hirao, S | 1 |
| Yamamoto, R | 1 |
| Hayakawa, T | 1 |
| Onaya, J | 1 |
| Kyogashima, M | 1 |
| Sunose, A | 1 |
| Miyauchi, S | 1 |
| Mizuno, S | 1 |
| Horie, K | 1 |
| Takagi, K | 1 |
| Isaji, S | 1 |
| Hirano, T | 1 |
| Manabe, T | 1 |
| Tobe, T | 1 |
| Satake, K | 1 |
| Koh, I | 1 |
| Nishiwaki, H | 1 |
| Umeyama, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes[NCT04996264] | Phase 2 | 96 participants (Actual) | Interventional | 2021-08-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for nafamostat and Disease Models, Animal
| Article | Year |
|---|---|
Site-specific therapeutic effects of protease inhibitors: effect of route of administration in experimental pancreatitis.
Topics: Animals; Benzamidines; Disease Models, Animal; Guanidines; Infusions, Intravenous; Pancreatitis, Acu | 2001 |
32 other studies available for nafamostat and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Nafamostat-Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; COVID-19; COVID-19 Drug Treatment; C | 2021 |
Nafamostat protects against early brain injury after subarachnoid hemorrhage in mice.
Topics: Animals; Benzamidines; Brain; Brain Injuries; Cells, Cultured; Cerebrovascular Circulation; Disease | 2022 |
Evaluation of the Antiviral Efficacy of Subcutaneous Nafamostat Formulated with Glycyrrhizic Acid against SARS-CoV-2 in a Murine Model.
Topics: Animals; Antiviral Agents; COVID-19; Disease Models, Animal; Glycyrrhizic Acid; Humans; Mice; Pandem | 2023 |
Effects of nafamostat mesilate on 5-hydroxytryptamine release from isolated ileal tissues induced by anti-cancer drugs in rats.
Topics: Animals; Benzamidines; Cisplatin; Disease Models, Animal; Guanidines; Ileum; Intestine, Small; Male; | 2020 |
A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite.
Topics: Animals; Antivenins; Asia; Benzamidines; Central America; Dimercaprol; Disease Models, Animal; Drug | 2020 |
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Topics: Angiotensin-Converting Enzyme 2; Animals; Benzamidines; Cells, Cultured; COVID-19 Drug Treatment; Di | 2021 |
Nafamostat mesilate attenuates inflammation and apoptosis and promotes locomotor recovery after spinal cord injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Benzamidines; Disease Models, Animal; F | 2018 |
Prevention of early liver metastasis after pancreatectomy by perioperative administration of a nuclear factor-κB inhibitor in mice.
Topics: Animals; Benzamidines; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; | 2019 |
Perforin and granzymes work in synergy to mediate cholangiocyte injury in experimental biliary atresia.
Topics: Animals; Animals, Newborn; Benzamidines; Bile Ducts; Biliary Atresia; CD8-Positive T-Lymphocytes; Ch | 2014 |
The effect of serine protease inhibitors on airway inflammation in a chronic allergen-induced asthma mouse model.
Topics: Allergens; Animals; Asthma; Benzamidines; Disease Models, Animal; Gabexate; Glycoproteins; Guanidine | 2014 |
Nafamostat mesilate attenuates transient focal ischemia/reperfusion-induced brain injury via the inhibition of endoplasmic reticulum stress.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocytes; Benzamidines; Br | 2015 |
Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats.
Topics: Animals; Behavior, Animal; Benzamidines; Disease Models, Animal; Guanidines; Infarction, Middle Cere | 2016 |
Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barré syndrome.
Topics: Animals; Benzamidines; Complement C3; Complement Inactivating Agents; Disease Models, Animal; Guanid | 2008 |
Nafamostat mesilate, a potent serine protease inhibitor, inhibits airway eosinophilic inflammation and airway epithelial remodeling in a murine model of allergic asthma.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Benzamidines; Bronchoalveolar Lavage Fluid | 2008 |
Involvement of Tryptase and Proteinase-Activated Receptor-2 in Spontaneous Itch-Associated Response in Mice With Atopy-like Dermatitis.
Topics: Animals; Benzamidines; Chronic Disease; Dermatitis, Atopic; Disease Models, Animal; Dose-Response Re | 2009 |
The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart.
Topics: Animals; Antibodies, Monoclonal; Benzamidines; Complement C3; Complement Inactivating Agents; Diabet | 2009 |
Inhibition of intraluminal pancreatic enzymes with nafamostat mesilate improves clinical outcomes after hemorrhagic shock in swine.
Topics: Analysis of Variance; Animals; Benzamidines; Disease Models, Animal; Drug Evaluation, Preclinical; D | 2010 |
Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamidines; Blotting, Western; Cell Cycle; Cell Line, T | 2010 |
The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice.
Topics: Acute Disease; Animals; Benzamidines; Capsaicin; Ceruletide; Disease Models, Animal; Gene Expression | 2010 |
Nafamostat mesilate attenuates colonic inflammation and mast cell infiltration in the experimental colitis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Blotting, West | 2011 |
Continuous regional application of protease inhibitor in the treatment of acute pancreatitis. An experimental study using closed duodenal obstruction model in dogs.
Topics: Animals; Benzamidines; Disease Models, Animal; Dogs; Duodenal Obstruction; Guanidines; Infusions, In | 2001 |
Serine proteases are involved in the pathogenesis of trauma-hemorrhagic shock-induced gut and lung injury.
Topics: Animals; Benzamidines; Cell Adhesion Molecules; Disease Models, Animal; Guanidines; Ileum; Intestina | 2003 |
Rat experimental model of continuous regional arterial infusion of protease inhibitor and its effects on severe acute pancreatitis.
Topics: Animals; Benzamidines; Celiac Artery; Disease Models, Animal; Guanidines; Infusions, Intra-Arterial; | 2005 |
Nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Disease Models, Animal; Guanidines; | 2007 |
Effects of direct haemoperfusion through fibres immobilizing polymyxin B and nafamostat mesilate on endotoxaemia in conscious Guinea-pigs.
Topics: Animals; Anticoagulants; Benzamidines; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Colon; | 2008 |
The effect of 6-amidino-2-naphtyl-4-guanidinobenzoate dimethane sulfonate (FUT-175) on experimental glomerulonephritis in mice.
Topics: Animals; Benzamidines; Complement Inactivator Proteins; Cyclophosphamide; Disease Models, Animal; Fe | 1984 |
Activation of trypsinogen in experimental models of acute pancreatitis in rats.
Topics: Acute Disease; alpha-Macroglobulins; Animals; Benzamidines; Ceruletide; Disease Models, Animal; Guan | 1995 |
Effects of dermatan sulfate, a heparin cofactor II mediated thrombin inhibitor, on the endotoxin-induced disseminated intravascular coagulation model in the rat: comparison with low-molecular weight heparin, nafamostat mesilate and argathroban.
Topics: Animals; Arginine; Benzamidines; Dermatan Sulfate; Disease Models, Animal; Disseminated Intravascula | 1998 |
Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model.
Topics: Acute Disease; Amylases; Animals; Anti-Bacterial Agents; Bacterial Infections; Bacterial Translocati | 2000 |
[The cellular and lysosomal fragility of pancreatic acinar cells after ligation of pancreatico-biliary duct in the rat and the protective effects of nafamostat mesilate].
Topics: Acute Disease; Amylases; Animals; Benzamidines; Body Water; Cathepsin B; Disease Models, Animal; Gua | 1992 |
Toxic products in hemorrhagic ascitic fluid generated during experimental acute hemorrhagic pancreatitis in dogs and a treatment which reduces their effect.
Topics: Acute Disease; Animals; Ascitic Fluid; Benzamidines; Disease Models, Animal; Dogs; Female; Guanidine | 1985 |